Melatonin supplementation as an adjuvant therapy in neonatal respiratory distress syndrome

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200326001

Enrollment

Unknown

Registered

2020-03-26

Start date

2016-06-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

respiratory distress syndrome neonates respiratory distress syndrome

Interventions

melatonin in a dosage of 10 mg/kg daily as a single daily dose for 5 days through an orogastric tube,Oxygen

Experimental Drug,Active Comparator Drug

Melatonin,control

Eligibility

Sex/Gender

All

Age

0 Days to 28 Days

Inclusion criteria

Inclusion criteria: neonates respiratory distress syndrome

Exclusion criteria

Exclusion criteria: age more than 28 days

Design outcomes

Primary

Measure	Time frame
decreased Malondialdehyde (MDA) and increased Superoxide Dismutase (SOD) 10 months ELISA	—

Secondary

Measure	Time frame
decreased Interleukin-8(IL-8) 12 months ELISA	—

Countries

Egypt

Contacts

Public ContactMohamed Elfarargy

Tanta University Hospital

farargy2009@hotmail.com00201005171750

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026